This is the point that can easily get lost when an exciting scientific discovery becomes a viral story.
The hydrogel is not currently a treatment available to people who have suffered a heart attack.
It has not been established as a cure.
It has not been demonstrated to regenerate human heart muscle in clinical practice.
Favaloro University describes Ferrer's work as being in the preclinical stage, while the university and IMETTyB identify her as part of the laboratory developing the technology.
Recent scientific reviews likewise emphasize that most hydrogel-based cardiac regeneration strategies remain preclinical and that clinical translation is still limited. A 2026 review specifically noted that although preclinical studies have demonstrated reductions in infarct size and improvements in cardiac function, clinical translation remains constrained by issues including safety, manufacturing, standardization and long-term efficacy.
That distinction is not a reason to dismiss the research.
It is exactly why the research matters.
Medical breakthroughs rarely move directly from a laboratory concept to a hospital.
They pass through years of experiments, failures, redesigns, safety testing and carefully controlled clinical trials.
The Difficult Road From Discovery to Patients
Even if the hydrogel continues to produce positive results, several major challenges remain.
Safety
The heart is an unforgiving organ.
An injected material must not trigger dangerous inflammation, abnormal scarring, toxicity or other complications.
Researchers must also understand how the material breaks down and what happens to its components over time.
Delivery
It is not enough for a hydrogel to work in principle.
Doctors must be able to deliver it accurately and consistently to the appropriate region of the heart.
The method of injection itself must be safe.
Manufacturing
A promising laboratory formulation is not automatically a manufacturable medicine.
The material must be produced consistently, at a quality suitable for clinical use, and under tightly controlled conditions.
Every batch needs to behave predictably.
Long-term effectiveness
A result measured after several weeks is only the beginning.
Researchers need to know whether improvements persist for months or years.
Does the regenerated or repaired tissue remain functional?
Does the hydrogel prevent adverse remodeling?
Does it reduce the long-term risk of heart failure?
These questions can only be answered through longer and more extensive studies.
Human clinical trials
Eventually, if preclinical evidence is strong enough and regulatory requirements are met, the technology would need to be evaluated in human trials.
Early trials generally focus heavily on safety.
Later-stage trials are designed to determine whether a treatment actually provides meaningful clinical benefits.
Only after that process could a therapy potentially become part of routine medical practice.
A Broader Revolution in Regenerative Medicine
Ferrer’s project is part of a much larger scientific movement.
For decades, cardiovascular medicine has focused primarily on restoring blood flow, preventing another heart attack and supporting the heart when its function is impaired.
Those approaches have saved countless lives.
But regenerative medicine asks a different question.
Instead of simply managing the consequences of tissue loss, can we help the body rebuild some of what has been lost?
Hydrogels are only one strategy.
Researchers are also studying stem cells, extracellular vesicles, tissue-engineered patches, biomaterials, gene-based approaches and combinations of several technologies.
Some hydrogels are designed to deliver growth factors.
Others carry cells or extracellular vesicles.
Some are engineered to respond to environmental changes.
Others attempt to reproduce the electrical or mechanical characteristics of healthy cardiac tissue.
The field is therefore evolving from the idea of a simple “patch” toward increasingly sophisticated systems that attempt to communicate with the biology of the injured heart.
Recent reviews describe injectable hydrogels as potentially useful not only as physical scaffolds but also as platforms for delivering therapeutic molecules and modifying the local cardiac microenvironment.
Why Pilar Ferrer's Age Has Captured Attention
The science is the real story, but Ferrer's age has naturally made the project especially compelling.